## Protocol Section
### Identification Module
**NCT ID:** NCT04960579

**Acronym:** MM

**Brief Title:** P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

**Official Title:** Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

#### Organization Study ID Info
**ID:** P-BCMA-ALLO1-001
#### Organization
**Class:** INDUSTRY
**Full Name:** Poseida Therapeutics, Inc.
### Status Module
#### Completion Date
**Date:** 2039-12

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-02-29

**Type:** ACTUAL

**Last Update Submit Date:** 2024-02-27

**Overall Status:** RECRUITING

#### Primary Completion Date
**Date:** 2027-12

**Type:** ESTIMATED

#### Start Date
**Date:** 2022-05-05

**Type:** ACTUAL

**Status Verified Date:** 2024-02

#### Study First Post Date
**Date:** 2021-07-14
**Type:** ACTUAL
**Study First Submit Date:** 2021-06-24
**Study First Submit QC Date:** 2021-07-09
### Sponsor Collaborators Module

#### Collaborators

**Class:** INDUSTRY

**Name:** Roche-Genentech

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Poseida Therapeutics, Inc.

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

**Detailed Description:** Phase 1/1b study: Phase 1 Part 1 is a weight-based dose escalation following a 3+3 design of dose-escalating cohorts. Phase 1 Part 2 includes administration at fixed doses. After enrollment, subjects may receive a lymphodepletion therapy regimen before administration of allogeneic CAR-T cells, administered as a single or multiple doses. Treated subjects will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated. Phase 1b of the study will undergo further expansion of cohorts/arms from Phase 1 Parts 1 or 2 to guide selection of Recommended Phase 2 Dose (RP2D).

### Conditions Module

**Conditions:**

- Multiple Myeloma

### Design Module

#### Design Info

**Allocation:** NON_RANDOMIZED

**Intervention Model:** SINGLE_GROUP

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 231

**Type:** ESTIMATED

**Phases:**

- PHASE1

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm S)

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen F.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm F)

**Type:** EXPERIMENTAL

#### Arm Group 3

**Description:** Single weight-based IV administration of P-BCMA-ALLO1. Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm N)

**Type:** EXPERIMENTAL

#### Arm Group 4

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm P1)

**Type:** EXPERIMENTAL

#### Arm Group 5

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P2.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm P2)

**Type:** EXPERIMENTAL

#### Arm Group 6

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen R.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm R)

**Type:** EXPERIMENTAL

#### Arm Group 7

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RS.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm RS)

**Type:** EXPERIMENTAL

#### Arm Group 8

**Description:** Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen C.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm C)

**Type:** EXPERIMENTAL

#### Arm Group 9

**Description:** Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm160)

**Type:** EXPERIMENTAL

#### Arm Group 10

**Description:** Single fixed dose IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen S, P1, P1.5 or P2.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm480)

**Type:** EXPERIMENTAL

#### Arm Group 11

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen P1.5.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm P1.5)

**Type:** EXPERIMENTAL

#### Arm Group 12

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm RP1)

**Type:** EXPERIMENTAL

#### Arm Group 13

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP1.5.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm RP1.5)

**Type:** EXPERIMENTAL

#### Arm Group 14

**Description:** Single weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen RP2.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm RP2)

**Type:** EXPERIMENTAL

#### Arm Group 15

**Description:** Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm CP1)

**Type:** EXPERIMENTAL

#### Arm Group 16

**Description:** Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP1.5.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm CP1.5)

**Type:** EXPERIMENTAL

#### Arm Group 17

**Description:** Cyclic weight-based IV administration of P-BCMA-ALLO1 following conditioning chemotherapy regimen CP2.

Rimiducid may be administered as indicated.

**Intervention Names:**

- Biological: P-BCMA-ALLO1 CAR-T cells

- Drug: Rimiducid

**Label:** P-BCMA-ALLO1 CAR-T cells (Arm CP2)

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- P-BCMA-ALLO1 CAR-T cells (Arm C)

- P-BCMA-ALLO1 CAR-T cells (Arm CP1)

- P-BCMA-ALLO1 CAR-T cells (Arm CP1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm CP2)

- P-BCMA-ALLO1 CAR-T cells (Arm F)

- P-BCMA-ALLO1 CAR-T cells (Arm N)

- P-BCMA-ALLO1 CAR-T cells (Arm P1)

- P-BCMA-ALLO1 CAR-T cells (Arm P1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm P2)

- P-BCMA-ALLO1 CAR-T cells (Arm R)

- P-BCMA-ALLO1 CAR-T cells (Arm RP1)

- P-BCMA-ALLO1 CAR-T cells (Arm RP1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm RP2)

- P-BCMA-ALLO1 CAR-T cells (Arm RS)

- P-BCMA-ALLO1 CAR-T cells (Arm S)

- P-BCMA-ALLO1 CAR-T cells (Arm160)

- P-BCMA-ALLO1 CAR-T cells (Arm480)

**Description:** Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy

**Name:** P-BCMA-ALLO1 CAR-T cells

**Type:** BIOLOGICAL

#### Intervention 2

**Arm Group Labels:**

- P-BCMA-ALLO1 CAR-T cells (Arm C)

- P-BCMA-ALLO1 CAR-T cells (Arm CP1)

- P-BCMA-ALLO1 CAR-T cells (Arm CP1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm CP2)

- P-BCMA-ALLO1 CAR-T cells (Arm F)

- P-BCMA-ALLO1 CAR-T cells (Arm N)

- P-BCMA-ALLO1 CAR-T cells (Arm P1)

- P-BCMA-ALLO1 CAR-T cells (Arm P1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm P2)

- P-BCMA-ALLO1 CAR-T cells (Arm R)

- P-BCMA-ALLO1 CAR-T cells (Arm RP1)

- P-BCMA-ALLO1 CAR-T cells (Arm RP1.5)

- P-BCMA-ALLO1 CAR-T cells (Arm RP2)

- P-BCMA-ALLO1 CAR-T cells (Arm RS)

- P-BCMA-ALLO1 CAR-T cells (Arm S)

- P-BCMA-ALLO1 CAR-T cells (Arm160)

- P-BCMA-ALLO1 CAR-T cells (Arm480)

**Description:** Safety switch activator

**Name:** Rimiducid

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** Rate of dose limiting toxicities (DLT)

**Measure:** Phase 1 Part 1: Assess the safety and maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT)

**Time Frame:** Baseline through Day 28

**Description:** Frequency and severity of adverse events, including cytokine release syndrome.

**Measure:** Phase 1 Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.

**Time Frame:** Baseline through 36 months

**Description:** Incidence and severity of cytokine release syndrome (CRS) events graded using American Society for Transplantation and Cellular Therapy (ASTCT) criteria (Lee, 2019).

**Measure:** Phase 1b: The effect of cell dose and study arm to guide selection of Recommended Phase 2 Dose (RP2D).

**Time Frame:** Baseline through 36 months

#### Secondary Outcomes

**Description:** Incidence and severity of treatment-emergent adverse events

**Measure:** The safety of P-BCMA-ALLO1

**Time Frame:** Baseline through 15 years

**Description:** According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Response Rate (ORR) - Percentage of patients with complete response (CR), very good partial response (VGPR), or partial response (PR)

**Measure:** The anti-myeloma effect of P-BCMA-ALLO1 (ORR) in Phase 1 Parts 1 and 2

**Time Frame:** Baseline through 15 years

**Description:** According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Time to Response (TTR) - Time to complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease

**Measure:** The anti-myeloma effect of P-BCMA-ALLO1 (TTR)

**Time Frame:** Baseline through 15 years

**Description:** According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Duration of Response - Time from complete response (CR), very good partial response (VGPR), or partial response (PR) to progressive disease

**Measure:** The anti-Myeloma effect of P-BCMA-ALLO1 (DOR)

**Time Frame:** Baseline through 15 years

**Description:** According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Progression Free Survival (PFS) - Time from P-BCMA-ALLO1 treatment to progressive disease

**Measure:** The anti-Myeloma effect of P-BCMA-ALLO1 (PFS)

**Time Frame:** Baseline through 15 years

**Description:** According to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma: Overall Survival (OS) - Duration of survival from time of treatment with P-BCMA-ALLO1

**Measure:** The anti-Myeloma effect of P-BCMA-ALLO1 (OS)

**Time Frame:** Baseline through 15 years

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

1. Must have signed written, informed consent.
2. Males or females, ≥18 years of age.
3. Must have a confirmed diagnosis of active MM.
4. Must have measurable MM.
5. Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
6. Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-BCMA-ALLO1 administration.
7. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion therapy regimen (females of childbearing potential).
8. Must be at least 90 days since autologous stem cell transplant, if performed.
9. Must have adequate vital organ function within pre-determined parameters.
10. Must have recovered from toxicities due to prior therapies.
11. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Exclusion Criteria:

1. Is pregnant or lactating.
2. Has inadequate venous access.
3. Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, or amyloidosis.
4. Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma.
5. Has active autoimmune disease.
6. Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc.
7. Has an active systemic infection.
8. Has a history of hepatitis B, hepatitis C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome. Subjects with a history of treated hepatitis C can be enrolled if negative by Hepatitis C PCR on multiple occasions and with medical monitor approval.
9. Is positive for cytomegalovirus (CMV) by PCR, CMV immunoglobulin M (IgM) antibody, or Coronavirus disease 2019 (COVID-19) by PCR.
10. Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia.
11. Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol.
12. Has received prior allogeneic cellular therapy or gene therapy.
13. Has received anti-cancer medications within 2 weeks of the time of initiating conditioning LD therapy.
14. Has received monoclonal antibody therapy within 4 weeks of initiating conditioning LD therapy.
15. Has received immunosuppressive medications within 2 weeks of the time of administration of P-BCMA-ALLO1, and/or expected to require them while on study.
16. Has received systemic corticosteroid therapy within 1 week or 5 half-lives (whichever is shorter) of the administration of P-BCMA-ALLO1 or is expected to require it during the course of the study.
17. Has CNS metastases or symptomatic CNS involvement of their myeloma.
18. Has a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
19. Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.
20. Arms R, RS, RP1, RP1.5 and RP2 Only: a) Has received a live vaccine within the last 28 days of the first administration of agents used in Arm R or RS, b) Has any known hypersensitivity or severe reactions or toxicity to agents used in Arms R or RS.

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** clinicaltrials@poseida.com

**Name:** Angie Schinkel

**Phone:** 858-779-3103

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** San Diego

**Country:** United States

**Facility:** University of California San Diego

**State:** California

**Status:** RECRUITING

**Zip:** 92093

**Location 2:**

**City:** San Francisco

**Country:** United States

**Facility:** University of California San Francisco

**State:** California

**Status:** TERMINATED

**Zip:** 94143

**Location 3:**

**City:** Park Ridge

**Country:** United States

**Facility:** Advocate Aurora Health

**State:** Illinois

**Status:** TERMINATED

**Zip:** 66068

**Location 4:**

**City:** Iowa City

**Country:** United States

**Facility:** University of Iowa

**State:** Iowa

**Status:** RECRUITING

**Zip:** 52242

**Location 5:**

**City:** Kansas City

**Country:** United States

**Facility:** University of Kansas Medical Center

**State:** Kansas

**Status:** RECRUITING

**Zip:** 66160

**Location 6:**

**City:** Baltimore

**Country:** United States

**Facility:** University of Maryland Greenebaum Comprehensive Cancer Center

**State:** Maryland

**Status:** RECRUITING

**Zip:** 21201

**Location 7:**

**City:** Detroit

**Country:** United States

**Facility:** Wayne State - Karmanos Cancer Institute

**State:** Michigan

**Status:** RECRUITING

**Zip:** 48201

**Location 8:**

**City:** Buffalo

**Country:** United States

**Facility:** Roswell Park Comprehensive Cancer Center

**State:** New York

**Status:** RECRUITING

**Zip:** 14263

**Location 9:**

**City:** Cincinnati

**Country:** United States

**Facility:** University of Cincinnati

**State:** Ohio

**Status:** RECRUITING

**Zip:** 45221

**Location 10:**

**City:** Oklahoma City

**Country:** United States

**Facility:** University of Oklahoma, Health Sciences Center

**State:** Oklahoma

**Status:** ACTIVE_NOT_RECRUITING

**Zip:** 73104

**Location 11:**

**City:** Nashville

**Country:** United States

**Facility:** Vanderbilt University Medical Center

**State:** Tennessee

**Status:** RECRUITING

**Zip:** 37232

**Location 12:**

**City:** Austin

**Country:** United States

**Facility:** Sarah Cannon Research Institute - St. David's South Austin Medical Center

**State:** Texas

**Status:** RECRUITING

**Zip:** 78704

**Location 13:**

**City:** Houston

**Country:** United States

**Facility:** Houston Methodist Research Institute

**State:** Texas

**Status:** RECRUITING

**Zip:** 77030

**Location 14:**

**City:** San Antonio

**Country:** United States

**Facility:** Sarah Cannon Research Institute - Methodist Healthcare

**State:** Texas

**Status:** RECRUITING

**Zip:** 78229

#### Overall Officials

**Official 1:**

**Affiliation:** Vice President, Clinical Development

**Name:** Rajesh Belani, M.D.

**Role:** STUDY_DIRECTOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000009370

- Term: Neoplasms by Histologic Type

- ID: D000009369

- Term: Neoplasms

- ID: D000020141

- Term: Hemostatic Disorders

- ID: D000014652

- Term: Vascular Diseases

- ID: D000002318

- Term: Cardiovascular Diseases

- ID: D000010265

- Term: Paraproteinemias

- ID: D000001796

- Term: Blood Protein Disorders

- ID: D000006402

- Term: Hematologic Diseases

- ID: D000006474

- Term: Hemorrhagic Disorders

- ID: D000008232

- Term: Lymphoproliferative Disorders

- ID: D000007160

- Term: Immunoproliferative Disorders

- ID: D000007154

- Term: Immune System Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC04

- Name: Neoplasms

- Abbrev: BC14

- Name: Heart and Blood Diseases

- Abbrev: BC15

- Name: Blood and Lymph Conditions

- Abbrev: BC20

- Name: Immune System Diseases

- Abbrev: All

- Name: All Conditions

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M12058

- Name: Multiple Myeloma

- Relevance: HIGH

- As Found: Multiple Myeloma

- ID: M27588

- Name: Neoplasms, Plasma Cell

- Relevance: HIGH

- As Found: Multiple Myeloma

- ID: M12315

- Name: Neoplasms by Histologic Type

- Relevance: LOW

- As Found: Unknown

- ID: M21977

- Name: Hemostatic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M5059

- Name: Blood Coagulation Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M17400

- Name: Vascular Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M13178

- Name: Paraproteinemias

- Relevance: LOW

- As Found: Unknown

- ID: M5077

- Name: Blood Protein Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M9490

- Name: Hematologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M9560

- Name: Hemorrhagic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M11225

- Name: Lymphoproliferative Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M10206

- Name: Immunoproliferative Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M10200

- Name: Immune System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: T3947

- Name: Multiple Myeloma

- Relevance: HIGH

- As Found: Multiple Myeloma

### Condition Browse Module - Meshes

- ID: D000009101

- Term: Multiple Myeloma

- ID: D000054219

- Term: Neoplasms, Plasma Cell

### Misc Info Module

- Version Holder: 2024-05-24
